Clinical data | |
---|---|
Trade names | Fetroja, Fetcroja |
Other names | Cephiderocol, RSC-649266 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620008 |
License data | |
Routes of administration | Intravenous infusion |
Drug class | Siderophore cephalosporin[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 56–58%[2] |
Elimination half-life | 2.8 hours |
Excretion | Mainly kidney (60–70% unchanged) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C30H34ClN7O10S2 |
Molar mass | 752.21 g·mol−1 |
3D model (JSmol) | |
| |
|
Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections and hospital acquired pneumonia.[3] It is used when other treatments might not work, including for Pseudomonas aeruginosa.[4][3] It is given by injection into a vein.[3]
Common side effects include diarrhea, pain at the site of injection, constipation, rash, candidiasis, liver problems, and low potassium.[3] Other side effects may include anaphylaxis, Clostridioides difficile infection, and seizures.[3] Safety in pregnancy is unclear.[3] It is in the cephalosporin family of medications.[3]
Cefiderocol was approved for medical use in the United States in 2019 and Europe in 2020.[3][4] It is on the World Health Organization's List of Essential Medicines.[5] In the United Kingdom 5 doses costs about £1,300.[6] This amount in the United States is about 2,000 USD.[7]
References
edit- ^ "Cefiderocol Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 30 December 2021.
- ^ Katsube, T.; Echols, R.; Arjona Ferreira, J. C.; et al. (2017). "Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment". Journal of Clinical Pharmacology. 57 (5): 584–591. doi:10.1002/jcph.841. PMC 5412848. PMID 27874971.
- ^ a b c d e f g h i j "Fetroja- cefiderocol sulfate tosylate injection, powder, for solution". DailyMed. 19 November 2019. Archived from the original on 1 February 2021. Retrieved 29 April 2020.
- ^ a b c "Fetcroja EPAR". European Medicines Agency (EMA). 24 February 2020. Archived from the original on 17 September 2020. Retrieved 29 April 2020. This article incorporates text from this source, which is in the public domain.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 562. ISBN 978-0857114105.
- ^ "Fetroja Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 30 December 2021.